The global Antibody Drug Conjugates market size is expected to grow at a CAGR of 25% over the forecast period. Increasing cancer incidence with a growing elderly population is likely to drive the antibody-drug conjugate (ADC) market. In addition, major technological advances are contributing to growth. According to the World Health Organization (WHO), the population aged 65 and over is expected to reach from 7% in 2000 to 16% of the total population by 2050. Aging has become a significant risk factor for numerous diseases, including cancer. Others. Therefore, a growing elderly population is expected to drive the growth of the market during the forecast period.
A full report of Antibody Drug Conjugates Market available at https://www.orionmarketreports.com/antibody-drug-conjugates-market/11594/
The report provides extensive competitive analysis and profiles of key market players, such as, include F. Hoffman-La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Seattle Genetics Inc., Genentech Inc., Immunogen Inc., Immunomedics, Inc., Progenics Pharmaceuticals Inc. and Bayer Healthcare Pharmaceuticals.
The other players in the value chain include Agensys, Inc., Concortis Biotherapeutics, Sanofi S.A., Celldex Therapeutics Inc., and Synthon Holding B.V.
Antibody Drug Conjugates Market: Segmentation
By Drugs
• Adcetris
• Kadcyla
By Mechanism Of Action
• CD30 Antibodies
• HER2 Antibodies
By Application
• Breast Cancer
• Lymphoma
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
